Software Spotting Fibrotic Lung Disease Gets FDA's Class II Label
Published Date: 10/30/2026
Rule
Summary
The FDA is officially putting radiology software that helps spot fibrotic lung disease into a safer, easier-to-manage category called Class II. This change, effective October 30, 2026, means the software will have special safety rules but face fewer hurdles, helping patients get access to new tech faster. Doctors, hospitals, and software makers will feel the impact, with smoother approval and no surprise costs.
Analyzed Economic Effects
6 provisions identified: 3 benefits, 2 costs, 1 mixed.
Premarket 510(k) required for makers
The device is subject to the premarket notification requirement under section 510(k) of the FD&C Act (FDA has not exempted this device type from 510(k)). Manufacturers must submit a 510(k) to market these Class II devices.
Compliance burdens for device developers
To meet the Class II special controls, device developers must perform clinical validation under anticipated conditions, run postmarket surveillance per FDA timelines, perform software verification/validation and hazard analysis, and produce detailed labeling and technical documentation. These requirements create testing, monitoring, and documentation work for manufacturers.
Faster patient access via Class II move
The FDA has classified radiology software for referral of findings related to fibrotic lung disease as Class II with special controls, effective October 30, 2026 (classification applicable January 12, 2024). FDA says this lower-device-class placement reduces regulatory burdens and will enhance patients' access to these devices.
New safety, testing, and labeling rules
FDA requires special controls including clinical performance validation testing, postmarket surveillance, software verification and validation, and detailed labeling (e.g., compatible hardware, performance summaries, limitations, and warnings). These controls are intended to reduce risks like false positives, false negatives, misuse, and device failures.
Creates a predicate for future devices
FDA states that by classifying this device type into Class I or II via De Novo, the device can serve as a predicate for future devices, allowing other sponsors to use the less-burdensome 510(k) process instead of De Novo or premarket approval. This can simplify and speed future market entry for similar devices.
Prescription-only device status
At the time of classification, these radiology software devices are designated for prescription use only. As prescription devices, they are exempt from the requirement for layperson directions for use if the conditions of 21 CFR 801.109 are met.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20848, Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods
The FDA is changing food rules to allow salt substitutes in many standardized foods, helping companies make lower-sodium options. This move aims to cut heart disease risks by reducing sodium without changing how foods basically taste or look. The new rule kicks in December 14, 2026, and food makers have until November 12, 2026, to raise any concerns, with no big costs expected.
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
Previous / Next Documents
Previous: 2026-22179, Medical Devices; General and Plastic Surgery Devices; Classification of the Software-Aided Adjunctive Diagnostic Device for Use by Physicians on Lesions Suspicious for Skin Cancer
The FDA is officially classifying a special software tool that helps doctors check skin spots that might be cancer into a safer, easier-to-manage category called Class II. This change, effective October 30, 2026, means the device will have clear safety rules but face fewer hurdles, helping patients get access to new tech faster. Doctors and device makers will benefit from this smoother process without extra costs or delays.
Next: 2026-22181, Medical Devices; Anesthesiology Devices; Classification of the Spinal Imaging System for Neuraxial Procedures
The FDA is officially putting spinal imaging systems used in neuraxial procedures into Class II, meaning they’ll have special safety rules but less red tape than before. This change helps make sure these devices are safe and effective while speeding up patient access to new tech. The new classification took effect on October 30, 2026, but has been in place since January 19, 2024, so manufacturers should already be on board.